Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness and Safety of Vibozilimod for Adults with Moderate to Severe Plaque Psoriasis

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment for moderate to severe plaque psoriasis, a skin condition that causes red, scaly patches on the skin. The treatment being tested is called SCD-044, which is taken in the form of tablets. The active ingredient in these tablets is vibozilimod, a type of medicine known as a selective immunosuppressive agent. This means it works by selectively reducing the activity of the immune system, which can help in managing the symptoms of psoriasis.

The purpose of this study is to determine how effective and safe SCD-044 is in treating moderate to severe plaque psoriasis. Participants in the study will be randomly assigned to receive either the SCD-044 tablets or a placebo, which looks like the real medication but does not contain the active ingredient. The study will last for up to 52 weeks, and participants will take the tablets orally. The main goal is to see if there is at least a 75% improvement in the severity and area of psoriasis after 16 weeks of treatment.

Throughout the study, participants will be monitored to assess the effectiveness of the treatment and to ensure their safety. The study aims to provide valuable information on whether SCD-044 can be a beneficial treatment option for those suffering from moderate to severe plaque psoriasis. This research could potentially lead to new ways to manage this challenging skin condition.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient must provide written informed consent. This confirms understanding and agreement to participate in the study.

    Eligibility is confirmed through a diagnosis of moderate to severe plaque psoriasis, with specific criteria such as body surface area involvement of at least 10%, a Psoriasis Area and Severity Index (PASI) score of 12 or more, and an Investigator's Global Assessment (IGA) of at least moderate disease.

  2. Step 2

    Treatment phase

    The patient will receive one of the following treatments: SCD-044 Tablets at doses of 0.1mg, 0.3mg, 0.6mg, or 1.0mg, or a placebo. The medication is taken orally.

    The treatment is administered daily for a period of 16 weeks.

  3. Step 3

    Monitoring and assessment

    Throughout the study, the patient's condition is monitored to assess the effectiveness and safety of the treatment.

    The primary goal is to determine if there is at least a 75% improvement in the PASI score by Week 16.

  4. Step 4

    Completion of the study

    At the end of the 16-week treatment period, the patient's progress is evaluated to determine the overall effectiveness of the treatment.

    The study aims to conclude by July 21, 2025.

Who can join the trial?

8 criteria

  • Must be a male or a non-pregnant, non-breastfeeding female who is 18 years or older.
  • Must provide written consent to participate in the study before any study-related activities begin.
  • Must have been diagnosed with mainly plaque psoriasis for at least 6 months. This will be confirmed by talking to the patient and a physical check-up by the study doctor.
  • Must be someone who could be treated with light therapy (phototherapy) or medication that affects the whole body (systemic therapy) for plaque psoriasis. However, these treatments will not be allowed during the study.
  • Must have moderate to severe plaque psoriasis at the start of the study, which means:
  • Psoriasis covers at least 10% of the body surface area (BSA).
  • A Psoriasis Area and Severity Index (PASI) score of 12 or higher. PASI is a tool used to measure the severity and extent of psoriasis.
  • An Investigator's Global Assessment (IGA) score of at least 3, indicating moderate disease. IGA is a scale used to assess the overall severity of psoriasis.

Who cannot join the trial?

10 criteria

  • Patients who are pregnant or breastfeeding cannot participate.
  • Individuals with a history of severe allergic reactions to similar treatments are excluded.
  • Patients with other skin conditions that might interfere with the study results are not eligible.
  • People with certain infections or diseases that affect the immune system cannot join the study.
  • Participants who have used similar treatments recently may be excluded.
  • Individuals with a history of drug or alcohol abuse might not be allowed to participate.
  • Patients with certain heart conditions or uncontrolled high blood pressure are excluded.
  • People who are currently participating in another clinical trial cannot join this study.
  • Individuals with a history of cancer, except for some types of skin cancer, may be excluded.
  • Patients who have had major surgery recently might not be eligible.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

SCD-044 is a medication being studied for its potential to treat moderate to severe plaque psoriasis. The goal of the trial is to see how effective SCD-044 is in improving the condition of the skin in patients with this type of psoriasis. Researchers are looking to see if patients experience at least a 75% improvement in their psoriasis symptoms after 16 weeks of treatment with SCD-044.

What is already known about the treatment

SCD-044 – SCD-044 is an investigational medication currently being studied for its potential to treat moderate to severe plaque psoriasis. It is administered orally in the form of tablets. The medication is in the clinical trial phase, with ongoing research to evaluate its effectiveness and safety. The main therapeutic indication for SCD-044 is to improve skin symptoms in individuals with plaque psoriasis. At the molecular level, SCD-044 works by modulating specific pathways involved in the inflammatory process, which are believed to contribute to the development of psoriasis. It is classified pharmacologically as an immunomodulator, aiming to reduce inflammation and skin cell proliferation associated with the condition.

Investigated diseases

Moderate to Severe Plaque Psoriasis – This is a chronic skin condition characterized by the development of thick, red patches covered with silvery-white scales. These patches, known as plaques, can appear anywhere on the body but are most commonly found on the elbows, knees, scalp, and lower back. The disease progresses through cycles, with periods of flare-ups followed by times of remission. During flare-ups, the plaques can become itchy, painful, and may crack or bleed. The severity of the condition can vary, with moderate to severe cases involving larger areas of the body and more intense symptoms. The exact cause is not fully understood, but it is believed to involve an immune system dysfunction that accelerates the growth cycle of skin cells.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-506477-35-00Protocol codeSCD-044-19-14Estimated enrolment240 patientsSponsorSun Pharmaceutical Industries Limited

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.